Condition: Adult Solid Tumor · Advanced Solid Tumor · Refractory Tumor · Sponsor: DeuterOncology
This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative. The dose escalation is completed, Part 2 of the study is ongoing.
This description comes directly from the study's public registry record.
Timothy Perera, PhD · +32473558353 · tperera@deuteroncology.com
Desirée Kanters · dkanters@deuteroncology.com
Always discuss trial participation with your own doctor first.
| Institut Roi Albert II - UC Louvain | Brussels, Belgium | Recruiting |
| UZA | Edegem, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Institut Bergonie | Bordeaux, France | Recruiting |
| Institut Cœur Poumon - CHU Lille | Lille, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hôpitaux Universitaires de Marseille Timone | Marseille, France | Not Yet Recruiting |
| Centre Antoine Lacassagne | Nice, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire De Rennes | Rennes, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Not Yet Recruiting |
| Radboud UMC | Nijmegen, Netherlands | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05752552